Literature DB >> 32022725

Treatment targets based on autoregulation parameters in neurocritical care patients.

Marek Czosnyka1, Peter Hutchinson, Peter Smielewski.   

Abstract

PURPOSE OF REVIEW: This review summarizes the physiological basis of autoregulation-oriented therapy in critically ill patients, with a particular emphasis on individual targets based on parameters that describe autoregulation of cerebral blood flow. RECENT
FINDINGS: The concepts of optimal cerebral perfusion (CPPopt) and arterial pressures (ABPopt), which both take advantage of continuous measures of cerebral autoregulation, recently have been introduced into clinical practice. It is hypothesized that if both pressures are used as individual targets and followed, the incidence and severity of dysautoregulation will diminish sufficiently to improve outcomes across the spectrum of acute neurological illnesses. These parameters have not been tested in randomized trials. However, a Phase II trial for CPPopt in Traumatic Brain Injury (COGITATE) is underway. Clinical series suggest that delirium following cardiac surgery may be reduced if blood pressure is actively regulated above the lower limit of autoregulation. In traumatic brain injury, using CPPopt as a single target allows monitoring of the upper and lower limits of autoregulation that provide a well tolerated 'corridor' for treatment. Pilot studies in which ABPopt is monitored in preterm newborns suggest fewer haemorrhagic events if blood pressure is closer to its optimal target. Brain imaging studies suggest worse tissue outcomes when blood pressure is below ABPopt.
SUMMARY: Targeted control of brain and systemic blood pressures to optimize cerebral autoregulation is of substantial interest to the neurocritical care and anaesthesia community, as this strategy may help to avoid secondary brain insults associated with ischemia or hyperaemia. The same strategy can be used outside the ICU (e.g. cardiac surgery, or in stroke patients after mechanical thrombectomy); this requires further research.

Entities:  

Mesh:

Year:  2020        PMID: 32022725     DOI: 10.1097/MCC.0000000000000704

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  6 in total

Review 1.  Regulation of cerebral blood flow in humans: physiology and clinical implications of autoregulation.

Authors:  Jurgen A H R Claassen; Dick H J Thijssen; Ronney B Panerai; Frank M Faraci
Journal:  Physiol Rev       Date:  2021-03-26       Impact factor: 37.312

2.  Making Waves: Will It Help Children with Traumatic Brain Injury?

Authors:  Shruti Agrawal
Journal:  Neurocrit Care       Date:  2021-07-15       Impact factor: 3.210

3.  Deviations from PRx-derived optimal blood pressure are associated with mortality after cardiac arrest.

Authors:  Matthew P Kirschen; Tanmay Majmudar; Ramon Diaz-Arrastia; Robert Berg; Benjamin S Abella; Alexis Topjian; Ramani Balu
Journal:  Resuscitation       Date:  2022-03-08       Impact factor: 6.251

Review 4.  Blood Pressure Management Following Large Vessel Occlusion Strokes: A Narrative Review

Authors:  Saurav Das; Kevin Denny John; Satheesh Kumar Bokka; Kerri Remmel; Ozan Akça
Journal:  Balkan Med J       Date:  2020-05-29       Impact factor: 2.021

5.  Continuous Time-Domain Cerebrovascular Reactivity Metrics and Discriminate Capacity for the Upper and Lower Limits of Autoregulation: A Scoping Review of the Animal Literature.

Authors:  Amanjyot Singh Sainbhi; Logan Froese; Alwyn Gomez; Carleen Batson; Kevin Y Stein; Arsalan Alizadeh; Frederick A Zeiler
Journal:  Neurotrauma Rep       Date:  2021-12-20

6.  Association of deranged cerebrovascular reactivity with brain injury following cardiac arrest: a post-hoc analysis of the COMACARE trial.

Authors:  Johanna Laurikkala; Anders Aneman; Alexander Peng; Matti Reinikainen; Paul Pham; Pekka Jakkula; Johanna Hästbacka; Erika Wilkman; Pekka Loisa; Jussi Toppila; Thomas Birkelund; Kaj Blennow; Henrik Zetterberg; Markus B Skrifvars
Journal:  Crit Care       Date:  2021-09-28       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.